Axogen Inc(AXGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.67 | Insider Own | 2.45% | Shs Outstand | 58.7M | Perf Week | 3.57% |
| Market Cap | 2.20B | Forward P/E | 53.62 | EPS next Y | 53.45% | Insider Trans | -8.67% | Shs Float | 57.2M | Perf Month | -13.61% |
| Enterprise Value | 2.10B | PEG | 1.06 | EPS next Q | 0.13 | Inst Own | 96.49% | Short Float | 8.95% | Perf Quarter | -9.45% |
| Income | -0.03B | P/S | 8.75 | EPS this Y | 56.97% | Inst Trans | 7.04% | Short Ratio | 4.15 | Perf Half Y | -10.79% |
| Sales | 0.25B | P/B | 7.84 | EPS next 5Y | 50.64% | ROA | -13.15% | Short Interest | 5.12M | Perf YTD | 14.45% |
| Book/sh | 4.78 | P/C | 19.38 | EPS past 3/5Y | 20.86% 10.54% | ROE | -18.21% | 52W High | -29.2% ($52.91) | Perf Year | 110.8% |
| Cash/sh | 1.93 | P/FCF | 255.56 | Sales past 3/5Y | 17.57% 14.93% | ROIC | -12.23% | 52W Low | 118.55% ($17.14) | Perf 3Y | 904.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -543.5% | Gross Margin | 74.56% | Volatility(W/M) | 3.86% 4.14% | Perf 5Y | 155.87% |
| Dividend TTM | - | EV/Sales | 8.38 | Sales Y/Y TTM | 23.57% | Oper. Margin | -5.12% | ATR (14) | 1.62 | Perf 10Y | 325.68% |
| Dividend Ex-Date | 2010/1/27 | Quick Ratio | 5.04 | EPS Q/Q | -334.71% | Profit Margin | -13.36% | RSI (14) | 43.8 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.6 | Sales Q/Q | 23.06% | SMA20 | 1.53% ($36.9) | Beta | 1.24 | Target Price | $53.09 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/10/28 | SMA50 | -12.48% ($42.8) | Rel Volume | 1.99 | Prev Close | $38.02 |
| Employees | 622 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | -1.15% 3.92% | SMA200 | -4.67% ($39.3) | Avg Volume(3M) | 1.24M | Price | $37.46 |
| IPO | 1986/12/17 | Option/Short | Yes/Yes | Trades | 15283 | Volume | 2,460,651 | Change | -1.47% |
🩺 This is a US medical device company that develops and supplies peripheral nerve repair and regeneration products. It offers surgical biologic products, including nerve grafts and nerve conduits for repairing damaged peripheral nerves, and operates a product portfolio specialized in the field of nerve damage repair resulting from trauma or surgery. It is a medical device company growing in the differentiated area of peripheral nerve repair.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded more than usual. That is 199% of its average volume.
Next earnings report: October 28
That is today.
AXGN has a sound balance sheet but weak earning power
Of every $100 in sales, $5.12 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +57.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $875. Peers typically go for $254.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +155.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 96.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #28 of 142 in the industry
Based on market cap of $2B.
FAQ
What kind of company is AXGN?
AXGN belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of AXGN?
The market cap of AXGN is approximately $2.2B, ranking 1,983 within its sector.
What is the 52-week high and low for AXGN?
AXGN has recorded a 52-week high of $52.91 and a low of $17.14.
